Needham, MA – According to filings with the U.S. Securities and Exchange Commission, Verastem is raising $4,829,628.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Robert Gagnon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Verastem

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. We are driven by the strength, tenacity and courage of those battling cancer single-minded in our resolve to deliver new therapies that not only keep cancer at bay but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.

To learn more about Verastem, visit http://www.verastem.com/

Contact:
Robert Gagnon, Chief Financial Officer
781-292-4200
rgagnon@verastem.com
https://www.linkedin.com/in/robert-gagnon-70b279/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved